New York, USA – August 3, 2022 – Recent research has shown that the complement receptors C3aR (C3a receptor) and C5aR (C5a receptor) function as a new class of immune checkpoint receptors, which are the targets of inhibition against inflammatory diseases. Therefore, Creative Biolabs announced to provide antagonist development services for C5aR and C3aR and to support the treatment of related diseases, such as rheumatoid arthritis and ischemia-reperfusion injury.
The complement system is an effector mechanism in immunity. It can be ignited in three distinct pathways: the classical pathway, the lectin pathway, and the alternative pathway.
* Classical pathway
11 proteins have been identified as the essential components of the classical route, including C1q, C1r, C1s, C2, C3, C4, C5, C6, C7, C8, and C9. Creative Biolabs offers a complete line of therapeutic antibodies, inhibitors, soluble complement regulators, as well as custom services based on the classical pathway targets, including:
a. C1 Complex
b. C1 Inhibitor
c. C2
d. C3
e. C4
f. C5
g. C5aR
* Lectin pathway
It has recently been demonstrated that both MASP-1 and MASP-2 are crucial to the lectin pathway activation. Creative Biolabs now provides custom services based on the lectin pathway targets, including:
a. MASP-1
b. MASP-2
* Alternative pathway
The shared components in the lectin pathway and the classical pathway are C3, C5, and C9, while the distinctive components are factor B, factor D, and factor P (properdin). Creative Biolabs can provide diverse solutions for the development of biotherapeutics for disease-related complement factors.
The following complement receptors, C3aR and C5aR, play important functions in the complement system and can be triggered by the aforementioned complement pathways.
C3a anaphylatoxin mediates multiple immunoregulatory activities by binding to the C3aR, which is predominantly distributed on leukocytes of myeloid lineages. Its major functions include eosinophil chemotaxis and the recruitment and degranulation of mast cells. As a small molecule, the C3aR antagonist SB 290157 reserved high market potential.
Based on the well-developed complement therapeutics platforms, Creative Biolabs provides custom C3aR antagonist development services to support the development of complement-related biopharmaceuticals.
The widespread expression of C5aR makes C5a a potential target for a range of inflammatory diseases, autoimmune diseases, neurodegenerative disorders, and tumors.
With years of experience in antibody drug development, Creative Biolabs developed anaphylatoxin receptor antagonists for global clients’ therapeutic studies.
According to a technician, “It has been demonstrated that PMX53 protects SIRI in the heart, liver, kidney, limb, and small intestine.” In addition, PMX53 and argatroban administration revealed a synergistic neuroprotective effect by lowering inflammatory factors and cerebral edema, which improves neurofunctional outcomes.
For more information about Creative Biolabs’ complement therapeutic discovery services, go to https://www.creative-biolabs.com/complement-therapeutics.
About Creative Biolabs
Creative Biolabs is proud to provide antibody, protein, and small-molecule drug development services for a range of diseases caused by excessive or uncontrolled activation of the complement system.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/complement-therapeutics
